JP2006517973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517973A5 JP2006517973A5 JP2006503567A JP2006503567A JP2006517973A5 JP 2006517973 A5 JP2006517973 A5 JP 2006517973A5 JP 2006503567 A JP2006503567 A JP 2006503567A JP 2006503567 A JP2006503567 A JP 2006503567A JP 2006517973 A5 JP2006517973 A5 JP 2006517973A5
- Authority
- JP
- Japan
- Prior art keywords
- case
- nominal flux
- photoaging
- thiazolidinedione compound
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000004907 flux Effects 0.000 claims 30
- 229940123464 Thiazolidinedione Drugs 0.000 claims 20
- -1 Thiazolidinedione compound Chemical class 0.000 claims 20
- 206010051246 Photodermatosis Diseases 0.000 claims 18
- 230000008845 photoaging Effects 0.000 claims 18
- 230000001815 facial effect Effects 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims 9
- 201000004681 Psoriasis Diseases 0.000 claims 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims 9
- 206010000496 acne Diseases 0.000 claims 9
- 201000008937 atopic dermatitis Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 201000004700 rosacea Diseases 0.000 claims 9
- 201000000849 skin cancer Diseases 0.000 claims 9
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 8
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 8
- 241001303601 Rosacea Species 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 229960005095 pioglitazone Drugs 0.000 claims 4
- 229960004586 rosiglitazone Drugs 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 229960001641 troglitazone Drugs 0.000 claims 4
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 4
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 4
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 claims 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 2
- 229950009226 ciglitazone Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940088679 drug related substance Drugs 0.000 claims 2
- 229950002375 englitazone Drugs 0.000 claims 2
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 claims 2
- 229950003707 farglitazar Drugs 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 238000000691 measurement method Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303609.2A GB0303609D0 (en) | 2003-02-17 | 2003-02-17 | Novel therapeutic method and compositions |
| PCT/US2004/004329 WO2004073622A2 (en) | 2003-02-17 | 2004-02-13 | Novel therapeutic method and compositions for topical administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517973A JP2006517973A (ja) | 2006-08-03 |
| JP2006517973A5 true JP2006517973A5 (enExample) | 2007-03-29 |
Family
ID=9953158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503567A Withdrawn JP2006517973A (ja) | 2003-02-17 | 2004-02-13 | 新規な治療方法および局所投与用組成物 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1594959A4 (enExample) |
| JP (1) | JP2006517973A (enExample) |
| GB (1) | GB0303609D0 (enExample) |
| WO (1) | WO2004073622A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050390A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| FR2894477A1 (fr) * | 2005-12-13 | 2007-06-15 | Galderma Res & Dev | Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques |
| IE20070129A1 (en) * | 2007-02-28 | 2008-12-24 | Giuliani Int Ltd | Ppar-gamma agonists stimulate enteric defensin expression |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| EP2805746B1 (en) | 2009-02-16 | 2020-05-06 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
| WO2011084824A1 (en) * | 2009-12-21 | 2011-07-14 | Sarah Bacus | Compositions and methods for increasing cellular fat and bleaching skin |
| US20110150856A1 (en) | 2009-12-21 | 2011-06-23 | Sarah Bacus | Compositions and methods for treatment of vitiligo |
| JP6301844B2 (ja) | 2012-02-09 | 2018-03-28 | ノグラ ファーマ リミテッド | 線維症の処置方法 |
| AU2013248397A1 (en) | 2012-04-18 | 2014-10-02 | Nogra Pharma Limited | Methods of treating lactose intolerance |
| AU2014236510A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| CA3037958C (en) | 2017-02-22 | 2022-06-14 | Jeffrey L. Sugarman | Glitazones for topical application |
| SI3921299T1 (sl) | 2019-02-08 | 2025-03-31 | Nogra Pharma Limited | Postopek izdelave 3-(4'-aminofenil)-2-metoksipropionske kisline in njenih analogov in vmesnih proizvodov |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2002076177A2 (en) * | 2001-03-23 | 2002-10-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for ppar |
| US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
| US6747048B2 (en) * | 2002-05-08 | 2004-06-08 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
-
2003
- 2003-02-17 GB GBGB0303609.2A patent/GB0303609D0/en not_active Ceased
-
2004
- 2004-02-13 WO PCT/US2004/004329 patent/WO2004073622A2/en not_active Ceased
- 2004-02-13 JP JP2006503567A patent/JP2006517973A/ja not_active Withdrawn
- 2004-02-13 EP EP04711167A patent/EP1594959A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517973A5 (enExample) | ||
| EP3240538B1 (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| ES2427822T3 (es) | Tratamiento de la diabetes tipo 2 con una combinación de inhibidor de DPIV y metformina o tiazolidinadiona | |
| HK1249401A1 (zh) | Ep-4受体拮抗剂在治疗il-23介导疾病中的用途 | |
| US20060229347A1 (en) | Treatment of eczemas | |
| US20070249561A1 (en) | Pharmacological method for treatment of neuropathic pain | |
| JP5952890B2 (ja) | 膵臓癌を治療するための医薬製剤 | |
| JP2020512337A5 (enExample) | ||
| HUP0300479A2 (hu) | PPAR-gamma agonisták alkalmazása neutrofil okozta betegségek kezelésére | |
| JP2012502103A5 (enExample) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| ES2693779T3 (es) | Ciclesonida para el tratamiento de enfermedades de las vías respiratorias en caballos | |
| WO2018035446A1 (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| JP2016537360A (ja) | 神経変性疾患を治療するための新規な方法 | |
| CN101500567B (zh) | P38激酶抑制剂治疗精神障碍的用途 | |
| JP5815273B2 (ja) | 抗炎症剤組成物 | |
| CA2603297A1 (en) | Oxaprozin or closely related compound for the treatment and prevention of | |
| JP5303093B2 (ja) | テナトプラゾール及びヒスタミンｈ２受容体拮抗剤を組み合わせた医薬組成物 | |
| CN108853141A (zh) | 油溶性富勒烯结构在制备抑制肿瘤生长药物中的应用 | |
| CN115038446A (zh) | 马赛替尼治疗嗜酸性粒细胞性哮喘的用途 | |
| JP4503942B2 (ja) | 止痒剤 | |
| AU2018355698A1 (en) | Non-steroidal selective glucocorticoid receptor agonistic modulators (SEGRAMs) and uses thereof | |
| DE10204398A1 (de) | Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR) | |
| TW200403989A (en) | Methods and compositions for treatment of cancer pain | |
| HK1089688A (en) | Oxaprozin or closely related compound for the treatment and prevention of pruritus |